BACKGROUND AND PURPOSE: Preoperative radiochemotherapy has been reported to enhance tumor response and to improve long-term survival in advanced squamous cell carcinoma of the head and neck. This retrospective study evaluates regression rate and long-term survival in 228 patients with primary oral squamous cell carcinoma treated by neoadjuvant radiochemotherapy and radical surgery. PATIENTS AND METHODS: All patients with biopsy-proven, resectable oral squamous cell carcinoma - TNM stages II-IV without distant metastasis - received preoperative treatment consisting of fractioned irradiation of the primary and the regional lymph nodes with a total dose of 40 Gy and additional cisplatin (n = 160) or carboplatin (n = 68) during the 1st week of treatment. Radical surgery and neck dissection followed after a delay of 10-14 days. The study only included cases with histologically negative resection margins. RESULTS: After a median follow-up of 5.2 years, 53 patients (23.2%) had experienced local-regional recurrence. The median 2-year disease-specific survival (DSS) rate was 86.2%. 5-year DSS and 10-year DSS were 76.3% and 66.7%, respectively. Complete histological local tumor regression after surgery (ypT0) was observed in 50 patients (21.9%) and was independent of pretreatment tumor classification. Uni- and multivariate survival analysis revealed that ypT- and ypN-stage were the most decisive predictors for DSS. CONCLUSION: Preoperative radiochemotherapy with cisplatin/carboplatin followed by radical surgery attains favorable long-term survival rates. This applies especially to cases with complete histological tumor regression after radiochemotherapy, which can be assumed for one of five patients.
BACKGROUND AND PURPOSE: Preoperative radiochemotherapy has been reported to enhance tumor response and to improve long-term survival in advanced squamous cell carcinoma of the head and neck. This retrospective study evaluates regression rate and long-term survival in 228 patients with primary oral squamous cell carcinoma treated by neoadjuvant radiochemotherapy and radical surgery. PATIENTS AND METHODS: All patients with biopsy-proven, resectable oral squamous cell carcinoma - TNM stages II-IV without distant metastasis - received preoperative treatment consisting of fractioned irradiation of the primary and the regional lymph nodes with a total dose of 40 Gy and additional cisplatin (n = 160) or carboplatin (n = 68) during the 1st week of treatment. Radical surgery and neck dissection followed after a delay of 10-14 days. The study only included cases with histologically negative resection margins. RESULTS: After a median follow-up of 5.2 years, 53 patients (23.2%) had experienced local-regional recurrence. The median 2-year disease-specific survival (DSS) rate was 86.2%. 5-year DSS and 10-year DSS were 76.3% and 66.7%, respectively. Complete histological local tumor regression after surgery (ypT0) was observed in 50 patients (21.9%) and was independent of pretreatment tumor classification. Uni- and multivariate survival analysis revealed that ypT- and ypN-stage were the most decisive predictors for DSS. CONCLUSION: Preoperative radiochemotherapy with cisplatin/carboplatin followed by radical surgery attains favorable long-term survival rates. This applies especially to cases with complete histological tumor regression after radiochemotherapy, which can be assumed for one of five patients.
Authors: P Lavertu; D J Adelstein; J P Saxton; M Secic; I Eliachar; M Strome; M A Larto; B G Wood Journal: Arch Otolaryngol Head Neck Surg Date: 1999-02
Authors: M Suntharalingam; M L Haas; D A Van Echo; R Haddad; M C Jacobs; S Levy; W C Gray; R A Ord; B A Conley Journal: Cancer Date: 2001-02-01 Impact factor: 6.860
Authors: H Wanebo; P Chougule; N Ready; H Safran; W Ackerley; R J Koness; R McRae; P Nigri; L Leone; K Radie-Keane; P Reiss; T Kennedy Journal: Ann Surg Oncol Date: 2001-09 Impact factor: 5.344
Authors: A S Garden; J Harris; E E Vokes; A A Forastiere; J A Ridge; C Jones; E M Horwitz; B S Glisson; L Nabell; J S Cooper; W Demas; E Gore Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Denis Soulieres; Neil N Senzer; Everett E Vokes; Manuel Hidalgo; Sanjiv S Agarwala; Lillian L Siu Journal: J Clin Oncol Date: 2004-01-01 Impact factor: 44.544
Authors: Christos Perisanidis; Gabriela Kornek; Paul W Pöschl; Daniel Holzinger; Katharina Pirklbauer; Christian Schopper; Rolf Ewers Journal: Med Oncol Date: 2013-01-06 Impact factor: 3.064
Authors: Maximilian Moergel; Philipp Meurer; Katharina Ingel; Thomas G Wendt; Bilal Al-Nawas Journal: Strahlenther Onkol Date: 2011-05-16 Impact factor: 3.621
Authors: Edwin Bölke; Gisela Schieren; Stephan Gripp; Gerald Steinbach; Matthias Peiper; Klaus Orth; Christiane Matuschek; Maximilian Pelzer; Guido Lammering; Ruud Houben; Christina Antke; Lars Christian Rump; Rodrigo Mota; Peter Arne Gerber; Patrick Schuler; Thomas K Hoffmann; Ethelyn Rusnak; Derik Hermsen; Wilfried Budach Journal: Strahlenther Onkol Date: 2011-02-24 Impact factor: 3.621
Authors: Tomasz Rutkowski; Andrzej Wygoda; Marcin Hutnik; Krzysztof Składowski; Jerzy Wydmański; Adam Maciejewski; Cezary Szymczyk; Janusz Wierzgoń; Andrzej Orlef; Bogusław Maciejewski Journal: Strahlenther Onkol Date: 2010-08-30 Impact factor: 3.621
Authors: Stefan Riml; Franz Böhler; Lorenz Larcher; Alexander de Vries; Wolfgang Elsässer; Peter Kompatscher Journal: Wien Klin Wochenschr Date: 2012-08-01 Impact factor: 1.704
Authors: Matthias Kreppel; Sarah Danscheid; Martin Scheer; Jan Christoffer Lüers; Hans Theodor Eich; Joachim E Zöller; Orlando Guntinas-Lichius; Dirk Beutner Journal: Chemother Res Pract Date: 2012-09-29